Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment

被引:3
|
作者
Wang, Chuanlin [1 ,2 ]
Gao, Pengning [1 ,2 ]
Xu, Jiali [1 ,2 ]
Liu, Shanling [1 ,2 ]
Tian, Wenda [2 ,3 ]
Liu, Jiayu [4 ]
Zhou, Lan [1 ,2 ]
机构
[1] Kunming Med Univ, Yunnan Canc Hosp, Dept Clin Nutr, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China
[2] Yunnan Canc Ctr, Kunming, Yunnan, Peoples R China
[3] Kunming Med Univ, Yunnan Canc Hosp, Dept Gynecol, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China
[4] Anhui Med Univ, Key Lab Environm Toxicol Anhui Higher Educ Inst, Sch Publ Hlth, Dept Toxicol, Hefei, Anhui, Peoples R China
关键词
phytochemicals; ovarian cancer; PARP; BRCA; PARP inhibitors; ANTIOXIDANT DEFENSE SYSTEM; ENDOTHELIAL DYSFUNCTION; DNA-REPAIR; DAMAGE; KEAP1; CROCIN; TUMORS; CELLS; NRF2; ROS;
D O I
10.3389/fphar.2022.1078303
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ovarian cancer is among the most common malignant tumors in gynecology and is characterized by insidious onset, poor differentiation, high malignancy, and a high recurrence rate. Numerous studies have shown that poly ADP-ribose polymerase (PARP) inhibitors can improve progression-free survival (PFS) in patients with BRCA-mutated ovarian cancer. With the widespread use of BRCA mutation and PARP inhibitor (PARPi) combination therapy, the side effects associated with BRCA mutation and PARPi have garnered attention worldwide. Mutations in the BRCA gene increase KEAP1-NRF2 ubiquitination and reduce Nrf2 content and cellular antioxidant capacity, which subsequently produces side effects such as cardiovascular endothelial damage and atherosclerosis. PARPi has hematologic toxicity, producing thrombocytopenia, fatigue, nausea, and vomiting. These side effects not only reduce patients' quality of life, but also affect their survival. Studies have shown that natural phytochemicals, a class of compounds with antitumor potential, can effectively prevent and treat the side effects of chemotherapy. Herein, we reviewed the role of natural phytochemicals in disease prevention and treatment in recent years, including sulforaphane, lycopene, catechin, and curcumin, and found that these phytochemicals have significant alleviating effects on atherosclerosis, nausea, and vomiting. Moreover, these mechanisms of action significantly correlated with the side-effect-producing mechanisms of BRCA mutations and PARPi. In conclusion, natural phytochemicals may be effective in alleviating the side effects of BRCA mutant ovarian cancer cells and PARP inhibitors.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated Ovarian Cancer
    Saleh, Naveed
    Copur, Mehmet Sitki
    ONCOLOGY-NEW YORK, 2019, 33 (07): : 293 - 294
  • [22] NATURAL HISTORY OF PATIENTS WITH BRCA-MUTATED HIGH GRADE EPITHELIAL OVARIAN CANCER (HGEOC) BEFORE THE ERA OF PARP INHIBITORS MAINTENANCE IN 1ST LINE TREATMENT
    Romeo, C.
    Meeus, P.
    Rodrigues, M.
    Leblanc, E.
    Floquet, A.
    Pautier, P.
    Marchal, F.
    Provansal, M.
    Campion, L.
    Causeret, S.
    Gourgou, S.
    Ray-Coquard, I.
    Classe, J-M
    Pomel, C.
    Rouge, T. De la Motte
    Barranger, E.
    Savoye, A. M.
    Guillemet, C.
    Gladieff, L.
    Petit, T.
    Rouzier, R.
    Labreveux, C.
    Courtinard, C.
    Joly, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A513 - A514
  • [23] Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context
    Gonzalez-Martin, Antonio
    Matulonis, Ursula A.
    Korach, Jacob
    Mirza, Mansoor R.
    Moore, Kathleen N.
    Wu, Xiaohua
    York, Whitney
    Gupta, Divya
    Lechpammer, Stanislav
    Monk, Bradley J.
    FUTURE ONCOLOGY, 2022, 18 (23) : 2505 - 2536
  • [24] ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer
    Kristeleit, R. S.
    Lorusso, D.
    Oaknin, A.
    Safra, T.
    Swisher, E. M.
    Bondarenko, I. M.
    Huzarski, T.
    Klat, J.
    Moiseyenko, V.
    Poka, R. L.
    Viola, L. S.
    Tankersley, C.
    Maloney, L.
    Goble, S.
    Unger, C.
    Dowson, A.
    Giordano, H.
    Oza, A. M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?
    Kristeleit, R. S.
    Moore, K. N.
    ANNALS OF ONCOLOGY, 2022, 33 (10) : 989 - 991
  • [26] Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA deficient ovarian cancer
    Yang, Shicheng
    Brown, Needa
    Campbell, Abigail L.
    Aggarwal, Kushi
    Dinulescu, Daniela M.
    Sridhar, Srinivas
    CANCER RESEARCH, 2023, 83 (07)
  • [27] Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
    Arjun Mittra
    Geraldine H. O’ Sullivan Coyne
    Jennifer Zlott
    Shivaani Kummar
    Robert Meehan
    Lawrence Rubinstein
    Lamin Juwara
    Deborah Wilsker
    Jiuping Ji
    Brandon Miller
    Tony Navas
    Katherine V. Ferry-Galow
    Andrea Regier Voth
    Ting-Chia Chang
    Shahanawaz Jiwani
    Ralph E. Parchment
    James H. Doroshow
    Alice P. Chen
    Cancer Chemotherapy and Pharmacology, 2024, 93 : 177 - 189
  • [28] PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports
    Collot, Thomas
    Niogret, Julie
    Carnet, Marion
    Chevrier, Sandy
    Humblin, Etienne
    Favier, Laure
    Bengrine-Lefevre, Leila
    Desmoulins, Isabelle
    Arnould, Laurent
    Boidot, Romain
    MOLECULAR MEDICINE REPORTS, 2021, 23 (01) : 1 - 8
  • [29] PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond
    Banerjee, Susana
    Kaye, Stan
    CURRENT ONCOLOGY REPORTS, 2011, 13 (06) : 442 - 449
  • [30] PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond
    Susana Banerjee
    Stan Kaye
    Current Oncology Reports, 2011, 13 : 442 - 449